A mysterious RNA found in breast cancer led scientists to uncover an entire hidden class of cancer-specific RNAs across ...

Grail continues facing significant challenges as its stock plummeted over 45% after its landmark NHS-Galleri trial failed to ...

The Primary Endpoint of Statistically Significant Combined Stage III-IV Reduction Was Not Met, However A Favorable Trend Was Observed Over Time GRAIL Announces U.S. Sales Force Expansion Based on ...

BIOPREVENT’ AI tool predicts transplant-related immune conflict and mortality risk using biomarkers, helping doctors ...

Khaberni - Early cancer detection technologies are undergoing a radical transformation with the emergence of multicancer blood tests (MCED), which rely on the analysis of free DNA ...

Background and objectives Lung cancer remains the leading cause of cancer-related mortality worldwide. Early detection of pulmonary nodules is crucial for timely diagnosis and effective treatment.

GRAIL reported that 2025 total revenue rose 17% year on year to $147.2 million, driven by a 26% increase in U.S. Galleri sales to $136.8 million, while net loss narrowed sharply to $408.4 million and ...

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the fourth quarter and full year ...

An AI-led study in The BMJ flags nearly 10 per cent of global cancer research papers as potentially fake, raising alarms about paper mills and the integrity of cancer science worldwide ...